2021
DOI: 10.1186/s40792-021-01313-5
|View full text |Cite
|
Sign up to set email alerts
|

Four magnetic resonance imaging surveillance-detected breast cancer cases in cancer-free BRCA1/2 mutation carriers

Abstract: Background Hereditary breast and ovarian cancer (HBOC) syndrome is a susceptibility syndrome for cancers, such as breast and ovarian cancer, and BRCA1/2 are its causative genes. Annual breast-enhanced magnetic resonance imaging (MRI) is recommended for BRCA1/2 mutation carriers aged over 25 years as a secondary prevention of breast cancer. However, breast MRI surveillance is rarely performed in Japan, and only four cases of breast cancer diagnosis triggered by MRI surveillance have been reporte… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1
1

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 10 publications
0
2
0
Order By: Relevance
“…Risk-reducing surgery can thus be considered cancer preventive medicine in the true sense of the word. However, in Japan, risk-reducing surgery is not covered by health insurance for patients without cancer [7]. At our hospital, CRRM costs about 605,000 yen (including tax), RRSO costs 880,000 yen (including tax), and hysterectomy and ovarian salpingectomy costs 1,210,000 yen (including tax).…”
Section: Discussionmentioning
confidence: 96%
See 1 more Smart Citation
“…Risk-reducing surgery can thus be considered cancer preventive medicine in the true sense of the word. However, in Japan, risk-reducing surgery is not covered by health insurance for patients without cancer [7]. At our hospital, CRRM costs about 605,000 yen (including tax), RRSO costs 880,000 yen (including tax), and hysterectomy and ovarian salpingectomy costs 1,210,000 yen (including tax).…”
Section: Discussionmentioning
confidence: 96%
“…However, these bene ts are only available to those who have already developed breast or ovarian cancer, and the current situation is that HBOC medical care remains an out-of-pocket expense for those who have not developed cancer [7]. We report on a patient undergoing out-of-pocket surveillance as an undiagnosed (cancer-free) HBOC who was diagnosed with noninvasive breast cancer and was able to receive breast cancer treatment and risk-reducing surgery simultaneously under insurance coverage.…”
mentioning
confidence: 99%